Contribution of the Exome Sequencing in Antenatal Period Behind Ultrasound Features Suggestive of a Rare Genetic Disease
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Fetal Malformation
- Sponsor
- University Hospital, Strasbourg, France
- Enrollment
- 90
- Locations
- 12
- Primary Endpoint
- Diagnostic contribution of the exome sequencing in antenatal period in comparison with the chromosomal analysis (CGH-array) realized in current health care
- Last Updated
- 5 years ago
Overview
Brief Summary
Congenital malformations concern 3% of pregnancies; most of them can be seen during pregnancy. For some malformations, an invasive sample (trophoblast biopsy or amniocentesis) is proposed to search a chromosomal abnormality by the technique of DNA chip. However, some strongly suggestive signs of a genetic (and not chromosomal) pathology have a very low diagnostic rate with this technique. In the absence of an etiological diagnosis, the prognosis for the unborn child is very difficult to assess, as we can't know if the fetal malformation is really isolated or associted to other unseen features as part of a syndromic condition.
For some malformations strongly suggestive of a genetic condition, we propose to realize an exome (i.e. all coding parts of the genome) sequencing of the trio (child and the 2 parents) with a delivery time compatible with the emergency situation of a pregnancy (6 weeks maximum). We will apply bioinformatics filters to analyse only genes known to be involved in the malformation present in the unborn child and thus avoid the identification of variants in unrelated genes. These lists of genes have been previously validated by the Rare Disease Health Sectors and the affiliated diagnostic laboratories. The selected malformations are: 1) anomalies of the central nervous system (microcephaly (<- 2DS) with anomalies of gyration, anomalies of the posterior fossa, anomalies of the midline except agenesis of the corpus callosum), 2) ophthalmological anomalies (microphthalmia, hyperplasia vitreous) and 3) renal abnormalities (large hyperechoic kidneys).
Investigators
Eligibility Criteria
Inclusion Criteria
- •Father and mother of an unborn child past the age of majority
- •Consent dated and signed by the mother and by the father
- •Father and mother able to understand the objectives and risks of the study
- •For the mother, pregnancy in progress (between 12 and 34 weeks)
- •For the mother, pregnancy with the presence of a malformation on ultrasound, confirmed by a doctor from the multidisciplinary diagnostic prenatal center, entering into the indications retained for this study
- •Clinical validation of the couple's eligibility by an expert for some of selected indications
- •Father and mother affiliated to a social protection health
Exclusion Criteria
- •Identified genetic or chromosomal abnormality explaining the observed malformation
- •Inability to give informations to the father and / or mother (father or mother in emergency or life-threatening situation)
- •Father and / or mother under the protection of justice
- •Father and / or mother under guardianship or curatorship
- •Nursing woman
Outcomes
Primary Outcomes
Diagnostic contribution of the exome sequencing in antenatal period in comparison with the chromosomal analysis (CGH-array) realized in current health care
Time Frame: 13 months
Comparison of the number of genetic diagnoses made by exome sequencing and by CGH-array.
Secondary Outcomes
- Feasibility study of carrying out exome sequencing in the antenatal period in terms of time to deliver results(13 months)
- Effects on pregnancy management and/or postnatal child care due to an etiological diagnosis(13 months)